0

Close
 
Upcoming Allied Market Research
2023
Anti-osteoporosis Therapy And Fracture Healing Market

Anti-Osteoporosis Therapy and Fracture Healing Market

by Drug Type (Bi-phosphates, Calcitonin, Estrogen or Hormone Replacement Therapy, Others), by Route of administration (Oral, Injectable, Others) and by DISTRIBUTION CHANNEL (Hospital Pharmacy, Drug Stores, Retail Pharmacy, E-commerce): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A11504
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Anti-osteoporosis Therapy And Fracture Healing Market

Request Now !

Osteoporosis disease is the most established disease that occurs due to less bone mineral density, which causes heavy risk of fractures and bone fragility. The disease occurs mostly in spine, hip, shoulder and forearm. Hip fractures are most common as nearly one-third of patients lose mobility and need long-term nursing. Furthermore, patients are unable to move, prolonged complications arising out of bed immobilization ultimately results into fatality. The diagnostic measures of osteoporosis include X-ray and radiography tests that are further acknowledged with bone density test. Moreover, the treatment of osteoporosis includes drugs such as Bio phosphates as alendronate, risedronate, Ibandronate and others. The Raloxifene drugs act as estrogen in females and thus, can be used in the treatment of osteoporosis in females. Furthermore, teriparatide is also a powerful drug that stimulates the new bone growth. The mode action of the drugs is mainly anabolic which affect not only bone remodeling but also in the healing the fracture. The human monoclonal antibody to RANKL is an anabolic drug to show the healing action in the animal model. Denosumab is the example of such drug showing the healing activity. There are studies going on still to find the potential effect on the anti-osteoporosis drugs on the action of the fracture healing.

COVID-19 Scenario analysis:

The COVID-19 pandemic has impacted the world as it made the population to face the lockdown. This led to the slow-down of the healthcare sectors and hospitals. The pandemic resulted in the decrease in growth of the market. Many patients faced the problems to consult hospitals for the treatment. This situation also impacted the market in the positive way by making the opportunities for new innovations in the anti-osteoporosis therapy and also fracture healing.

Top impacting factors: Market scenario analysis, Trends, Drivers, Impact Analysis

The increase in the prevalence of diseases like osteoporosis and surge in the number of the patients of this disease is expected to increase the growth of the market. The geriatric population is the main focus point for market players. Some of the other bone diseases are also contributing to increase in the growth of the market. Moreover, the increase in the expenditure of the research and development activities regarding the generation of the drugs is another factor responsible for the increase in the growth of the market. Also, the increase in the spread of the awareness about the osteoporosis diagnosis and treatment adds up to the growth of the market. Furthermore, increase in number of healthcare sectors like the trauma centers infrastructure, also leads to increase in the growth of the anti-osteoporosis therapy and fracture healing market.

However, the cases of complications seen while the treatment of the disease is in progress like the ulcers, irritable bowel syndrome and nausea are expected to hamper the growth of the market.

New product launches to flourish the market:

In September 2018, the U.S. Food and Drug Administration approved the launch of Risedronate Sodium Delayed release tablet in America. This drug was launched by Zydus Pharma Inc. It is used in the treatment of osteoporosis in postmenopausal women.

In April 2018, the Denosumab drug was approved by the Committee for Medicinal Products for Human use (CHMP) of the European Medicines Agency, for the company named Amgen, Inc. This drug is used to treat bone loss associated with prolonged systemic glucocorticoid therapy.

Surge in the usage of the anti-osteoporosis therapy drugs:

The increase in the incidences of the diseases like osteoporosis and other bone diseases lead to increase in the usage of the drugs. Moreover, the increase in the number of trauma centers at various places like remote areas can also help to surge the usage of the anti-osteoporosis therapy drugs.

 

          Key benefits of the report:

  • This study presents the analytical depiction of the global anti-osteoporosis therapy and fracture healing industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global anti-osteoporosis therapy and fracture healing market share.
  • The current market is quantitatively analyzed to highlight the global anti-osteoporosis therapy and fracture healing market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed global anti-osteoporosis therapy and fracture healing market analysis based on competitive intensity and how the competition will take shape in coming years.

         Questions answered in the anti-osteoporosis therapy and fracture healing market research report:

  • What are the leading market players active in the anti-osteoporosis therapy and fracture healing market?
  • What the current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What are the projections for the future that would help in taking further strategic steps?

 Anti-Osteoporosis Therapy and Fracture Healing Market Report Highlights

Aspects Details
By Drug Type
  • Bi-phosphates
  • Calcitonin
  • Estrogen or Hormone Replacement Therapy
  • Others
By Route of administration
  • Oral
  • Injectable
  • Others
By DISTRIBUTION CHANNEL
  • Hospital Pharmacy
  • Drug Stores
  • Retail Pharmacy
  • E-commerce
By Region
  • North America 
  • Europe 
  • Asia-Pacific 
  • Latin America 
  • The Middle East and Africa 
Key Market Players GlaxoSmithKline plc, Others., Novartis International AG, Pfizer Inc., F. Hoffmann-La Roche AG, Amgen, Inc., Eli Lily and Company, Johnson & Johnson, Activas Generics, Merck & Co., Ltd, Teva Pharmaceuticals Industries Ltd.
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET, BY DRUG TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Drug Type

    • 4.2. Bi-phosphates

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Calcitonin

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Estrogen Or Hormone Replacement Therapy

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Others

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET, BY ROUTE OF ADMINISTRATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Route Of Administration

    • 5.2. Oral

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Injectable

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Others

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET, BY DISTRIBUTION CHANNEL

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Distribution Channel

    • 6.2. Hospital Pharmacy

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Drug Stores

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Retail Pharmacy

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. E-commerce

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

  • CHAPTER 7: ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Drug Type

      • 7.2.3. Market Size and Forecast, By Route Of Administration

      • 7.2.4. Market Size and Forecast, By Distribution Channel

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Anti-osteoporosis Therapy And Fracture Healing Market

        • 7.2.6.1. Market Size and Forecast, By Drug Type
        • 7.2.6.2. Market Size and Forecast, By Route Of Administration
        • 7.2.6.3. Market Size and Forecast, By Distribution Channel

      • 7.2.7. Canada Anti-osteoporosis Therapy And Fracture Healing Market

        • 7.2.7.1. Market Size and Forecast, By Drug Type
        • 7.2.7.2. Market Size and Forecast, By Route Of Administration
        • 7.2.7.3. Market Size and Forecast, By Distribution Channel

      • 7.2.8. Mexico Anti-osteoporosis Therapy And Fracture Healing Market

        • 7.2.8.1. Market Size and Forecast, By Drug Type
        • 7.2.8.2. Market Size and Forecast, By Route Of Administration
        • 7.2.8.3. Market Size and Forecast, By Distribution Channel

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Drug Type

      • 7.3.3. Market Size and Forecast, By Route Of Administration

      • 7.3.4. Market Size and Forecast, By Distribution Channel

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Anti-osteoporosis Therapy And Fracture Healing Market

        • 7.3.6.1. Market Size and Forecast, By Drug Type
        • 7.3.6.2. Market Size and Forecast, By Route Of Administration
        • 7.3.6.3. Market Size and Forecast, By Distribution Channel

      • 7.3.7. Germany Anti-osteoporosis Therapy And Fracture Healing Market

        • 7.3.7.1. Market Size and Forecast, By Drug Type
        • 7.3.7.2. Market Size and Forecast, By Route Of Administration
        • 7.3.7.3. Market Size and Forecast, By Distribution Channel

      • 7.3.8. Italy Anti-osteoporosis Therapy And Fracture Healing Market

        • 7.3.8.1. Market Size and Forecast, By Drug Type
        • 7.3.8.2. Market Size and Forecast, By Route Of Administration
        • 7.3.8.3. Market Size and Forecast, By Distribution Channel

      • 7.3.9. Spain Anti-osteoporosis Therapy And Fracture Healing Market

        • 7.3.9.1. Market Size and Forecast, By Drug Type
        • 7.3.9.2. Market Size and Forecast, By Route Of Administration
        • 7.3.9.3. Market Size and Forecast, By Distribution Channel

      • 7.3.10. UK Anti-osteoporosis Therapy And Fracture Healing Market

        • 7.3.10.1. Market Size and Forecast, By Drug Type
        • 7.3.10.2. Market Size and Forecast, By Route Of Administration
        • 7.3.10.3. Market Size and Forecast, By Distribution Channel

      • 7.3.11. Russia Anti-osteoporosis Therapy And Fracture Healing Market

        • 7.3.11.1. Market Size and Forecast, By Drug Type
        • 7.3.11.2. Market Size and Forecast, By Route Of Administration
        • 7.3.11.3. Market Size and Forecast, By Distribution Channel

      • 7.3.12. Rest Of Europe Anti-osteoporosis Therapy And Fracture Healing Market

        • 7.3.12.1. Market Size and Forecast, By Drug Type
        • 7.3.12.2. Market Size and Forecast, By Route Of Administration
        • 7.3.12.3. Market Size and Forecast, By Distribution Channel

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Drug Type

      • 7.4.3. Market Size and Forecast, By Route Of Administration

      • 7.4.4. Market Size and Forecast, By Distribution Channel

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Anti-osteoporosis Therapy And Fracture Healing Market

        • 7.4.6.1. Market Size and Forecast, By Drug Type
        • 7.4.6.2. Market Size and Forecast, By Route Of Administration
        • 7.4.6.3. Market Size and Forecast, By Distribution Channel

      • 7.4.7. Japan Anti-osteoporosis Therapy And Fracture Healing Market

        • 7.4.7.1. Market Size and Forecast, By Drug Type
        • 7.4.7.2. Market Size and Forecast, By Route Of Administration
        • 7.4.7.3. Market Size and Forecast, By Distribution Channel

      • 7.4.8. India Anti-osteoporosis Therapy And Fracture Healing Market

        • 7.4.8.1. Market Size and Forecast, By Drug Type
        • 7.4.8.2. Market Size and Forecast, By Route Of Administration
        • 7.4.8.3. Market Size and Forecast, By Distribution Channel

      • 7.4.9. South Korea Anti-osteoporosis Therapy And Fracture Healing Market

        • 7.4.9.1. Market Size and Forecast, By Drug Type
        • 7.4.9.2. Market Size and Forecast, By Route Of Administration
        • 7.4.9.3. Market Size and Forecast, By Distribution Channel

      • 7.4.10. Australia Anti-osteoporosis Therapy And Fracture Healing Market

        • 7.4.10.1. Market Size and Forecast, By Drug Type
        • 7.4.10.2. Market Size and Forecast, By Route Of Administration
        • 7.4.10.3. Market Size and Forecast, By Distribution Channel

      • 7.4.11. Thailand Anti-osteoporosis Therapy And Fracture Healing Market

        • 7.4.11.1. Market Size and Forecast, By Drug Type
        • 7.4.11.2. Market Size and Forecast, By Route Of Administration
        • 7.4.11.3. Market Size and Forecast, By Distribution Channel

      • 7.4.12. Malaysia Anti-osteoporosis Therapy And Fracture Healing Market

        • 7.4.12.1. Market Size and Forecast, By Drug Type
        • 7.4.12.2. Market Size and Forecast, By Route Of Administration
        • 7.4.12.3. Market Size and Forecast, By Distribution Channel

      • 7.4.13. Indonesia Anti-osteoporosis Therapy And Fracture Healing Market

        • 7.4.13.1. Market Size and Forecast, By Drug Type
        • 7.4.13.2. Market Size and Forecast, By Route Of Administration
        • 7.4.13.3. Market Size and Forecast, By Distribution Channel

      • 7.4.14. Rest of Asia Pacific Anti-osteoporosis Therapy And Fracture Healing Market

        • 7.4.14.1. Market Size and Forecast, By Drug Type
        • 7.4.14.2. Market Size and Forecast, By Route Of Administration
        • 7.4.14.3. Market Size and Forecast, By Distribution Channel

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Drug Type

      • 7.5.3. Market Size and Forecast, By Route Of Administration

      • 7.5.4. Market Size and Forecast, By Distribution Channel

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Anti-osteoporosis Therapy And Fracture Healing Market

        • 7.5.6.1. Market Size and Forecast, By Drug Type
        • 7.5.6.2. Market Size and Forecast, By Route Of Administration
        • 7.5.6.3. Market Size and Forecast, By Distribution Channel

      • 7.5.7. South Africa Anti-osteoporosis Therapy And Fracture Healing Market

        • 7.5.7.1. Market Size and Forecast, By Drug Type
        • 7.5.7.2. Market Size and Forecast, By Route Of Administration
        • 7.5.7.3. Market Size and Forecast, By Distribution Channel

      • 7.5.8. Saudi Arabia Anti-osteoporosis Therapy And Fracture Healing Market

        • 7.5.8.1. Market Size and Forecast, By Drug Type
        • 7.5.8.2. Market Size and Forecast, By Route Of Administration
        • 7.5.8.3. Market Size and Forecast, By Distribution Channel

      • 7.5.9. UAE Anti-osteoporosis Therapy And Fracture Healing Market

        • 7.5.9.1. Market Size and Forecast, By Drug Type
        • 7.5.9.2. Market Size and Forecast, By Route Of Administration
        • 7.5.9.3. Market Size and Forecast, By Distribution Channel

      • 7.5.10. Argentina Anti-osteoporosis Therapy And Fracture Healing Market

        • 7.5.10.1. Market Size and Forecast, By Drug Type
        • 7.5.10.2. Market Size and Forecast, By Route Of Administration
        • 7.5.10.3. Market Size and Forecast, By Distribution Channel

      • 7.5.11. Rest of LAMEA Anti-osteoporosis Therapy And Fracture Healing Market

        • 7.5.11.1. Market Size and Forecast, By Drug Type
        • 7.5.11.2. Market Size and Forecast, By Route Of Administration
        • 7.5.11.3. Market Size and Forecast, By Distribution Channel

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning,2022

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Activas Generics

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Amgen, Inc.

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Eli Lily And Company

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. F. Hoffmann-La Roche AG

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. GlaxoSmithKline Plc

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Merck And Co., Ltd

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Novartis International AG

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Pfizer Inc.

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Teva Pharmaceuticals Industries Ltd.

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Johnson And Johnson

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

    • 9.11. Others.

      • 9.11.1. Company Overview

      • 9.11.2. Key Executives

      • 9.11.3. Company Snapshot

      • 9.11.4. Operating Business Segments

      • 9.11.5. Product Portfolio

      • 9.11.6. Business Performance

      • 9.11.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET FOR BI-PHOSPHATES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET FOR CALCITONIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET FOR ESTROGEN OR HORMONE REPLACEMENT THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET FOR INJECTABLE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET FOR HOSPITAL PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET FOR DRUG STORES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET FOR RETAIL PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET FOR E-COMMERCE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 20. U.S. ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 21. U.S. ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 22. U.S. ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 23. CANADA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 24. CANADA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 25. CANADA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 27. MEXICO ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 28. MEXICO ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 32. EUROPE ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 33. FRANCE ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 36. GERMANY ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 37. GERMANY ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 38. GERMANY ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 39. ITALY ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 40. ITALY ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 41. ITALY ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 42. SPAIN ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 45. UK ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 46. UK ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 47. UK ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 48. RUSSIA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 49. RUSSIA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 50. RUSSIA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 51. REST OF EUROPE ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 52. REST OF EUROPE ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 53. REST OF EUROPE ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 54. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 55. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 56. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 57. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 58. CHINA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 59. CHINA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 60. CHINA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 61. JAPAN ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 62. JAPAN ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 63. JAPAN ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 64. INDIA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 65. INDIA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 66. INDIA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 68. SOUTH KOREA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 69. SOUTH KOREA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 70. AUSTRALIA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 71. AUSTRALIA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 72. AUSTRALIA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 73. THAILAND ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 74. THAILAND ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 75. THAILAND ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 76. MALAYSIA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 77. MALAYSIA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 78. MALAYSIA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 79. INDONESIA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 80. INDONESIA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 81. INDONESIA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 82. REST OF ASIA PACIFIC ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 83. REST OF ASIA PACIFIC ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 84. REST OF ASIA PACIFIC ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 85. LAMEA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 86. LAMEA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 87. LAMEA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 88. LAMEA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 89. BRAZIL ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 90. BRAZIL ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 91. BRAZIL ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 92. SOUTH AFRICA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 93. SOUTH AFRICA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 94. SOUTH AFRICA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 95. SAUDI ARABIA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 96. SAUDI ARABIA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 97. SAUDI ARABIA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 98. UAE ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 99. UAE ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 100. UAE ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 101. ARGENTINA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 102. ARGENTINA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 103. ARGENTINA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 104. REST OF LAMEA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 105. REST OF LAMEA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 106. REST OF LAMEA ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 107. ACTIVAS GENERICS: KEY EXECUTIVES
  • TABLE 108. ACTIVAS GENERICS: COMPANY SNAPSHOT
  • TABLE 109. ACTIVAS GENERICS: OPERATING SEGMENTS
  • TABLE 110. ACTIVAS GENERICS: PRODUCT PORTFOLIO
  • TABLE 111. ACTIVAS GENERICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 112. AMGEN, INC.: KEY EXECUTIVES
  • TABLE 113. AMGEN, INC.: COMPANY SNAPSHOT
  • TABLE 114. AMGEN, INC.: OPERATING SEGMENTS
  • TABLE 115. AMGEN, INC.: PRODUCT PORTFOLIO
  • TABLE 116. AMGEN, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 117. ELI LILY AND COMPANY: KEY EXECUTIVES
  • TABLE 118. ELI LILY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 119. ELI LILY AND COMPANY: OPERATING SEGMENTS
  • TABLE 120. ELI LILY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 121. ELI LILY AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 122. F. HOFFMANN-LA ROCHE AG: KEY EXECUTIVES
  • TABLE 123. F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
  • TABLE 124. F. HOFFMANN-LA ROCHE AG: OPERATING SEGMENTS
  • TABLE 125. F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
  • TABLE 126. F. HOFFMANN-LA ROCHE AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 127. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 128. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 129. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 130. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 131. GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 132. MERCK AND CO., LTD: KEY EXECUTIVES
  • TABLE 133. MERCK AND CO., LTD: COMPANY SNAPSHOT
  • TABLE 134. MERCK AND CO., LTD: OPERATING SEGMENTS
  • TABLE 135. MERCK AND CO., LTD: PRODUCT PORTFOLIO
  • TABLE 136. MERCK AND CO., LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 137. NOVARTIS INTERNATIONAL AG: KEY EXECUTIVES
  • TABLE 138. NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT
  • TABLE 139. NOVARTIS INTERNATIONAL AG: OPERATING SEGMENTS
  • TABLE 140. NOVARTIS INTERNATIONAL AG: PRODUCT PORTFOLIO
  • TABLE 141. NOVARTIS INTERNATIONAL AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 142. PFIZER INC.: KEY EXECUTIVES
  • TABLE 143. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 144. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 145. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 146. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 147. TEVA PHARMACEUTICALS INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 148. TEVA PHARMACEUTICALS INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 149. TEVA PHARMACEUTICALS INDUSTRIES LTD.: OPERATING SEGMENTS
  • TABLE 150. TEVA PHARMACEUTICALS INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 151. TEVA PHARMACEUTICALS INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 152. JOHNSON AND JOHNSON: KEY EXECUTIVES
  • TABLE 153. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  • TABLE 154. JOHNSON AND JOHNSON: OPERATING SEGMENTS
  • TABLE 155. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 156. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 157. OTHERS.: KEY EXECUTIVES
  • TABLE 158. OTHERS.: COMPANY SNAPSHOT
  • TABLE 159. OTHERS.: OPERATING SEGMENTS
  • TABLE 160. OTHERS.: PRODUCT PORTFOLIO
  • TABLE 161. OTHERS.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET SEGMENTATION
  • FIGURE 2. GLOBAL ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET
  • FIGURE 3. SEGMENTATION ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET
  • FIGURE 11. ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET SEGMENTATION, BY BY DRUG TYPE
  • FIGURE 12. ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET FOR BI-PHOSPHATES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET FOR CALCITONIN, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET FOR ESTROGEN OR HORMONE REPLACEMENT THERAPY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET SEGMENTATION, BY ROUTE OF ADMINISTRATION
  • FIGURE 17. ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET FOR ORAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET FOR INJECTABLE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET SEGMENTATION, BY BY DISTRIBUTION CHANNEL
  • FIGURE 21. ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET FOR DRUG STORES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET FOR E-COMMERCE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 26. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 27. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 28. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 29. COMPETITIVE DASHBOARD
  • FIGURE 30. COMPETITIVE HEATMAP: ANTI-OSTEOPOROSIS THERAPY AND FRACTURE HEALING MARKET
  • FIGURE 31. Top player positioning, 2022
  • FIGURE 32. ACTIVAS GENERICS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 33. ACTIVAS GENERICS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 34. ACTIVAS GENERICS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 35. AMGEN, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 36. AMGEN, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 37. AMGEN, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 38. ELI LILY AND COMPANY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 39. ELI LILY AND COMPANY: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 40. ELI LILY AND COMPANY: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 41. F. HOFFMANN-LA ROCHE AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 42. F. HOFFMANN-LA ROCHE AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 43. F. HOFFMANN-LA ROCHE AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 44. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 45. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 46. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 47. MERCK AND CO., LTD: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 48. MERCK AND CO., LTD: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 49. MERCK AND CO., LTD: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 50. NOVARTIS INTERNATIONAL AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. NOVARTIS INTERNATIONAL AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 52. NOVARTIS INTERNATIONAL AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 53. PFIZER INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 55. PFIZER INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 56. TEVA PHARMACEUTICALS INDUSTRIES LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 57. TEVA PHARMACEUTICALS INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 58. TEVA PHARMACEUTICALS INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 59. JOHNSON AND JOHNSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 60. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 61. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 62. OTHERS.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 63. OTHERS.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 64. OTHERS.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now
RELATED TAGS

Purchase Full Report of
Anti-osteoporosis Therapy And Fracture Healing Market

Start reading.
This Report and over 67,132+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers